secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0001193125-25-035203
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ORIC updates registrational plans for lead drugs, extends cash runway into 2027
-------------------------------------------------------------------------------

- ORIC-944 first Phase 3 trial in mCRPC expected 1H 2026; combination dose escalation data in 1H and 2H 2025.
- ORIC-114 registrational focus on 1L NSCLC with Phase 3 trials planned 2026; 2L/2L+ registration deprioritized.
- Comprehensive NSCLC data update expected 2H 2025 including 1L EGFR exon 20 and atypical cohorts.
- Cash, cash equivalents and investments totaled $256M as of Dec 31, 2024; projected runway extended into 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000119312525035203/0001193125-25-035203-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000119312525035203/d830999d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-035203

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer